RESUMEN
The previously described lead compound 5 is a potent and selective V(1A) antagonist with affinity at both the rat and human receptor, but displays poor oral bioavailability and moderate clearance. We report herein the successful optimisation of the pharmacokinetic (PK) properties to afford the potent, selective, orally bioavailable and CNS penetrant compound 15f. A custom optimisation approach was required which demonstrated the value of using early, rapid in vivo PK studies to show improvements in oral exposure. Such assays may be of particular value where low oral bioavailability is anticipated to be multifactorial (e.g., permeability, gut wall metabolism and/or transport) where satisfactory modelling of in vitro data is likely to be difficult within a drug discovery context.
Asunto(s)
Antagonistas de los Receptores de Hormonas Antidiuréticas , Fenilalanina/análogos & derivados , Administración Oral , Animales , Disponibilidad Biológica , Humanos , Masculino , Péptidos/química , Fenilalanina/síntesis química , Fenilalanina/química , Fenilalanina/farmacocinética , Unión Proteica , Ratas , Ratas Wistar , Receptores de Vasopresinas/metabolismo , Estereoisomerismo , Relación Estructura-ActividadRESUMEN
The discovery of a novel series of 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamide antagonists of the vasopressin V(1A) receptor is disclosed. Compounds 47 and 48 were found to be high affinity, selective vasopressin V(1A) antagonists.
Asunto(s)
Amidas/síntesis química , Amidas/farmacología , Antagonistas de los Receptores de Hormonas Antidiuréticas , Descubrimiento de Drogas , Amidas/química , Compuestos Aza/síntesis química , Compuestos Aza/química , Compuestos Aza/farmacología , Células Cultivadas , Ciclización , Humanos , Hígado/metabolismo , Estructura Molecular , Unión Proteica/efectos de los fármacosRESUMEN
The discovery and structure-activity relationship of a novel series of indole-2-carboxamide antagonists of the cannabinoid CB(1) receptor is disclosed. Compound 26i was found to be a high potency, selective cannabinoid CB(1) antagonist.
Asunto(s)
Amidas/química , Indoles/química , Receptor Cannabinoide CB1/antagonistas & inhibidores , Amidas/síntesis química , Amidas/farmacocinética , Animales , Perros , Evaluación Preclínica de Medicamentos , Indoles/síntesis química , Indoles/farmacocinética , Masculino , Ratones , Modelos Moleculares , Ratas , Ratas Wistar , Receptor Cannabinoide CB1/metabolismo , Relación Estructura-ActividadRESUMEN
A series of 3-phenoxypropyl piperidine analogues have been discovered as novel ORL1 receptor agonists. Structure-activity relationships have been explored around the 3-phenoxypropyl region with several potent and selective analogues identified.